LAUSANNE. Access to new medicines in Switzerland is splitting by insurer, not only by diagnosis. Swiss public television, RTS, reported on Tuesday that basic insurance does not treat requests for drugs outside the official list in a consistent way. Some companies accept almost every request. Others refuse more than half. Last year nearly 80,000 applications were filed for medicines that compulsory insurance does not cover automatically.

The route is legal. Articles 71a to 71d of the health insurance ordinance let a doctor ask an insurer to pay, case by case, when a drug is used outside its listed purpose, when it is authorised in Switzerland but not on the Specialities List, or when it is not authorised here but is authorised for that illness in a recognised country. The treatment has to offer a significant benefit in a serious illness for which no effective, already reimbursed alternative exists. The insurer decides after asking its medical adviser. Automatic is the word that does not apply.

One pancreatic cancer drug, three answers

The same hospital, the same cancer, three insurers, and three different answers.

RTS used daraxonrasib, sold as Rasonque, as the case that makes the split visible. The US regulator approved it on 26 August for advanced pancreatic cancer. It is the first drug to hit mutated KRAS proteins, which drive more than 90 per cent of those cancers, and in trials it doubled median survival for patients whose disease had spread. Revolution Medicines, which put its European headquarters in Basel in 2025, filed with Swissmedic on 19 August.

Approval, if it comes, is not the end. Swissmedic takes more than a year on average for a new drug. The Federal Office of Public Health then has to agree a price before the drug joins the Specialities List and becomes automatic. In the United States the list price is about 40,000 dollars a month, roughly CHF 33,500. While that machinery turns, patients use the exception. RTS found one insurer refused daraxonrasib for lack of evidence, a second refused because it could not agree what it called a reasonable price, and a third, for a patient at the same hospital with the same diagnosis, agreed to pay for twelve months.

The champions and the losers have not changed

The pattern is older than this drug. In 2023 Pascal Rolle, in French-speaking Switzerland, was prescribed Elzonris for an aggressive blood and bone-marrow cancer. Swissmedic had authorised it. It was not on the Specialities List. His insurer said no. With a lawyer, he got the drug after seven months. His cancer is in remission. The delay was the policy.

A 2020 study for the government, which RTS obtained after a fight with the public health office, put the differences down to the way insurers judge benefit. The office changed the procedure in 2024 to make those judgments more alike. RTS could not show that the gap has closed. Solange Peters, head of oncology at Lausanne University Hospital and president of Oncosuisse, gave RTS her own tally for 2020 to 2025. “At the CHUV, we have the same champions, and the same losers. It has not changed since 2020.” A fresh federal evaluation of this off-label route is expected in 2027. Named approval rates, from 98 per cent at one insurer to 45 per cent at another, were already public this month.

Full access is falling, and the exception is rising

A survey by the European Federation of Pharmaceutical Industries and Associations says full access to new medicines in Switzerland has fallen from 64 per cent to 50 per cent. Reimbursement case by case has nearly doubled over the same period, from 15 per cent to 27 per cent. The exception is becoming a normal door. It is a door that does not open evenly. Some executives have warned they will launch later in Switzerland, or not at all, if prices here do not rise. That threat, if they mean it, lengthens the queue at the exception.

For a household the practical point is blunt. The basic package is the same at every insurer. The judgment on a drug that is not on the list is not. Anyone still thinking of switching has until 30 November to put a written notice in the current insurer’s hands. Choose the company you would want on the phone if a doctor has to ask for something the list does not yet name. The click that would make leaving easier is not here yet. The difference in answers already is.